Skip to content

We put inspiration into practice, finding viable solutions to complex challenges.

Great ideas are our starting point.

Research focus
September 28th, 2026

curATalk seminar series

On this year’s World Heart Day, Sep 29th, we are pleased to welcome Prof. Dr. med. Steffen Massberg, the Director of the Medical Clinic and Polyclinic I at LMU University Hospital Munich, as the speaker of our next curATalk about “Crosstalk of immunity and thrombosis: Novel targets for vascular disease and beyond”.

We are TRON

TRON is an independent non-profit translational research organization. We pursue new diagnostics and drugs for the treatment of diseases with high medical need. We apply our transdisciplinary competencies in genomics and immunology to develop novel platforms for the identification and validation of ‘omics’-based biomarkers, to modulate immune system components for use in personalized therapies. Collaborating with academia and industry, TRON executes research at the leading edge to support innovative drug design for human health.

Mainz.
Research equipment.
Ugur Sahin and Özlem Türeci.

Our new research building

Our new research building is currently under construction on the grounds of Mainz University Medical Center according to a concept by Nickl und Partner architects. This envisions a modern, light-flooded building with laboratory and office areas as well as communication zones with up to 10,800 m² of usable space, which will be integrated into the adjacent green areas and the listed Fichte settlement. As a result of intensive coordination with the city of Mainz and all parties involved, construction preparations have been initiated in record time.

Our new research building.

Our Research Focus

TRON conducts collaborative research on disease genomics and therapeutic modulation of the immune system. Specializing in cancer immunology and genomics, our research teams develop tailored bioinformatic and novel biostatistical approaches to identify and characterize disease-relevant molecular targets. We design and improve cutting edge technologies for biomarker discovery and biopharmaceutical development, including platforms for immune-based therapies such as RNA vaccines and cellular therapies.

Microscope.